| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | 10 mg/mL solution for injection/infusion |
| Reference number | 1989 |
| Indication | Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/04/2016 |
| NICE guidance | TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy |
| Commercial arrangement | PAS |